The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.


All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.
Capital Markets

Deals of the year 2007: AstraZeneca injects hope

The medicine proved not too bitter for AstraZeneca when it braved the debt markets in crisis-torn September. Waiting any longer might have been perilous.

Santander’s Italian disposal is the Real deal
Nigeria clears the decks
Big bet pays off for Fortis

GCA reaches out to buy US peer
Maxis maxes out
Mexico motors on local-currency deal
Bovespa floats on the wave it made

AstraZeneca plc (rated AA–/A1/AA–)
September 5, 2007
$8 billion equivalent issue:


Libor +30bp $650 million, due 2009
5.4% $1.75 billion, due 2012
5.9% $1.75 billion, due 2017
6.45% $2.75 billion, due 2037



September 12, 2007
5.125% €750 million, due 2017
Citi, Deutsche Bank, HSBC

 John Cole, vice-president, group finance at AstraZeneca

John Cole: "We had set out our stall"

AstraZeneca’s refinancing of its acquisition of US biotechnology firm MedImmune was one of the defining moments of the debt capital markets in 2007. This is in no small part because of the way in which the firm’s management coped with the stark transformation of investor sentiment from the takeover deal’s announcement, in April, to when AstraZeneca went to the bond markets to refinance it in September.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.

SUBSCRIBE ONLINE TODAY

Unlimited access to Euromoney.com and Asiamoney.com

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually

FREE 7 DAY TRIAL

Unlimited access to Euromoney.com and Asiamoney.com, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors

LOGIN NOW

Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree